Addex Therapeutics (ADXN) published new preclinical research showing its lead compound ADX71743—a selective negative allosteric modulator (NAM) of mGlu7—significantly influenced relevant preclinical outcomes. The update is supportive for the program’s science, but provides no revenue, efficacy, or clinical-stage milestones in the available text.
Addex Therapeutics (ADXN) published new preclinical research showing its lead compound ADX71743—a selective negative allosteric modulator (NAM) of mGlu7—significantly influenced relevant preclinical outcomes. The update is supportive for the program’s science, but provides no revenue, efficacy, or clinical-stage milestones in the available text.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
